Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
出版年份 2020 全文链接
标题
Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e000650
出版商
BMJ
发表日期
2020-08-27
DOI
10.1136/jitc-2020-000650
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study
- (2020) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort
- (2019) Neil H. Segal et al. EUROPEAN JOURNAL OF CANCER
- Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program
- (2019) J. Corral et al. Clinical & Translational Oncology
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Responders to anti-PD1 therapy: Long-term outcomes and responses to retreatment in melanoma (mel).
- (2019) Allison Betof Warner et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
- (2019) Edward B. Garon et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC
- (2019) Scott J. Antonia et al. Journal of Thoracic Oncology
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
- (2019) Audrey Simonaggio et al. JAMA Oncology
- Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age
- (2019) Nabil F. Saba et al. ORAL ONCOLOGY
- MA07.05 Immune Checkpoint Inhibitor (ICPi) Re-Challenge: Outcomes Analysis in a French National Cohort of Non-Small-Cell Lung Cancer (NSCLC) Patients
- (2019) E. Gobbini et al. Journal of Thoracic Oncology
- OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer
- (2019) M. Reck et al. Journal of Thoracic Oncology
- Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
- (2019) Kohei Fujita et al. Thoracic Cancer
- Basal subtype bladder tumours demonstrate a “hot” immunophenotype
- (2018) Anjelica Hodgson et al. HISTOPATHOLOGY
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- (2018) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
- (2018) A. Bernard-Tessier et al. EUROPEAN JOURNAL OF CANCER
- Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial
- (2018) Harriet M. Kluger et al. JOURNAL OF CLINICAL ONCOLOGY
- High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
- (2018) Saman Maleki Vareki Journal for ImmunoTherapy of Cancer
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
- (2017) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis
- (2015) L De Smedt et al. BRITISH JOURNAL OF CANCER
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
- (2014) C. Lebbe et al. ANNALS OF ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More